Source link : https://www.newshealth.biz/health-news/fda-okays-subcutaneous-ocrelizumab-for-ms/
The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of the anti-CD20 antibody ocrelizumab (Ocrevus Zunovo, Genentech) for treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The subcutaneous (SC) injection can be administered by a healthcare professional in approximately 10 minutes and is the first and only twice-a-year […]
Author : News Health
Publish date : 2024-09-13 19:00:42
Copyright for syndicated content belongs to the linked Source.
Categories